BiotechTube
Montis Biosciences

Montis Biosciences

Leuven, Belgium· Est.
montisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.5M

Overview

Montis Biosciences is a private, preclinical-stage biotech founded in 2021 and based in Leuven, Belgium. The company's core innovation is a platform for discovering dual-mechanism anti-C1q antibodies designed to inhibit the classical complement pathway while also modulating C1q's complement-independent effects on myeloid cells, offering a novel approach in neuroinflammation. With a lead program in Guillain-Barré syndrome and a partnered oncology asset, Montis is backed by a strong syndicate of life science investors including Pfizer Ventures and VIB.

Neuroinflammatory DiseasesAutoimmune DiseasesNeurodegenerative DiseasesOphthalmic DiseasesOncology

Technology Platform

Platform for discovering dual-mechanism antibodies targeting complement C1q to simultaneously inhibit the classical complement pathway and modulate C1q's complement-independent effects on myeloid cells (e.g., macrophages).

Funding History

1
Total raised:$4.5M
Seed$4.5M

Opportunities

The lead C1q program addresses high-unmet-need neuroinflammatory diseases like Guillain-Barré syndrome, where a dual-mechanism approach could be superior to pure complement inhibition.
The growing recognition of complement and myeloid dysfunction in neurodegenerative diseases (e.g., Alzheimer's) presents a substantial long-term expansion opportunity.

Risk Factors

High preclinical/clinical development risk associated with a novel, first-in-class dual-mechanism biology.
The company is pre-revenue and will require significant additional financing to advance its lead program.
Faces competition from other complement-targeting therapies in development for neurological indications.

Competitive Landscape

Competes in the complement therapeutics space, which includes companies like Apellis, Alexion/AstraZeneca, and Roche, but Montis's upstream, dual-targeting C1q approach is distinct. In neuroinflammation, it may compete with broader immunosuppressants and emerging neuro-immunology drugs. The CD93 oncology asset operates in the competitive LUSC space.

More companies in Immunotherapy / Immuno-Oncology →More companies in Belgium →